Who are Bosentan and Sildenafil's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bosentan-and-sildenafil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Bosentan and Sildenafil — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bosentan and Sildenafil (Bosentan and Sildenafil) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Endothelin receptor antagonist and phosphodiesterase-5 inhibitor combination. Area: Cardiovascular.

phase 3 Endothelin receptor antagonist and phosphodiesterase-5 inhibitor combination Endothelin receptors (ETA/ETB) and phosphodiesterase-5 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Bosentan and Sildenafil (Bosentan and Sildenafil) — Rigshospitalet, Denmark. Bosentan blocks endothelin-1 receptors while sildenafil inhibits phosphodiesterase-5, together reducing pulmonary vascular resistance and improving right ventricular function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bosentan and Sildenafil TARGET	Bosentan and Sildenafil	Rigshospitalet, Denmark	phase 3	Endothelin receptor antagonist and phosphodiesterase-5 inhibitor combination	Endothelin receptors (ETA/ETB) and phosphodiesterase-5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Endothelin receptor antagonist and phosphodiesterase-5 inhibitor combination class)

Rigshospitalet, Denmark · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bosentan and Sildenafil — Competitive Intelligence Brief. https://druglandscape.com/ci/bosentan-and-sildenafil. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab